IGC Pharma's Stock Price Target Raised to $4.75 by Ascendiant Capital

Ascendiant Capital maintains its "Buy" rating on IGC Pharma (IGC) and raises the price target to $4.75, up 5.56% from $4.50. This is the second positive update from the analyst, indicating potential growth in the stock value. IGC Pharma develops cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, period cramps, and chronic pain. The average target price for IGC Pharma is $3.63, implying an upside of 1,111.97% from the current price of $0.30.